期刊文献+

卵巢癌早期诊断6种肿瘤标记物研究进展 被引量:1

Progress of Six Tumor Markers on Early Diagnosis of Ovarian Cancer
下载PDF
导出
摘要 卵巢癌是妇科恶性肿瘤的首要死亡原因,早期诊断并进行干预可以明显改善卵巢癌患者的5年生存率。多年来研究者一直致力于寻找简便高效的早期诊断指标,如CA125/153/724、血浆磷脂溶血酸(LPA)、人附睾分泌蛋白4(HE4)、B7-H4分子、Prostasin基因、间皮素(Mesothelin)等。本文主要对近年来研究较多的肿瘤标记物做一综述。 Ovarian cancer is the primary death cause of gynecologic cancer, early diagnosis and intervention can significantly improve the 5-year ovarian cancer survival rate. Over the years researchers have been dedicated to finding the simple and effective tumor markers on early diagnosis,such as CA125/153/724,plasma lysphosphatidie acid (LPA),human epididymis protein 4 (HE4),B7-H4 molecules,prostasin genes, mesothelin, and so on. This paper focuses on more recent studies of tumor markers.
作者 于涓 王钱
出处 《中国现代医生》 2011年第18期29-31,共3页 China Modern Doctor
关键词 卵巢癌 早期诊断 CA125/153/724 血浆磷脂溶血酸 人附睾分泌蛋白4 B7-H4 PROSTASIN 间皮素 Ovarian cancer Early diagnosis CA 125/153/724 LPA HE4 B7-H4 Prostasin Mesothelin
  • 相关文献

参考文献31

  • 1Ye B,Gag~on A,Mok SC. Recent technical strategies to identify di- agnostic biomarkers for ovarian cancer[J]. Expert Rev Proteomies, 2007,4( 1 ) : 121-131.
  • 2Maeda T,Inoue M,Koshiba S,et al. Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16)[J]. J Biol Chem,2004,279(13):13174-13182.
  • 3Bast RC Jr. Status of tumor markers in ovarian cancer screening[J]. J Clin Oncol, 2003,21 ( 10 Suppl) : $200-$205.
  • 4Duffy MJ,Bonfrer JM,Kulpa J,et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use[J]. Int J Gynecol Cancer,2005,15(5 ) :679-691.
  • 5Nossov V,Amneus M,Su F,et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do bet- ter than serum CA-125?[J]. Am J Obstet Gynecol,2008,199(3):215-223.
  • 6Skates SJ,Horlck N,Yu Y,et al. Preoperative sensitivity and speci- ficity for early-stage ovarian cancer when combining cancer antigen CA-1251I, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions[J]. J Clin Oncol, 2004,22(20) : 4059-4066.
  • 7Kitajima M,Satoh G,Marusasa T,et al. A case of gastric cancer with peritoneal dissemination-efficacy of combination therapy with S-I and docetaxel[J]. Gan To Kagaku Ryoho,2009,36(9) : 1545-1548.
  • 8Kikkawa F,Nawa A,Kajiyama H,et al. Clinical characteristics and prognosis of mucinous tumors of the ovary[J]. Gynecol Oncol,2006,103(1):171-175.
  • 9Ubukata H, Katano M, Motohashi G,et al. Evaluation of CA72-4 as a tumor marker in patients with gastric cancer[J]. Gan To Kagaku Ry- oho, 2003,30( 11 ) : 1821-1824.
  • 10Moore RG,Brown AK,Miller MC ,et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecol Oncol,2008,108(2):402-408.

二级参考文献37

  • 1李山,秦雪,何卫华.血清CA125在卵巢癌诊断中的价值及文献评价[J].中华检验医学杂志,2005,28(2):209-211. 被引量:37
  • 2Chert LM, Skirtrter ML, Kaufnan SW et al. Prostasin is a Glycosylphosphatidylinositol - anchor - ed active serine protease. J Biol Chem, 2001, 276 (24): 21434
  • 3Ismail RS, Baldwin RL, Fang Jet al. Differential gene experesion between normal and tumor - derived ovarian epithelial cells. Cancer Res, 2000, 60 : 6744
  • 4Mok SC, Chao J, Skates Set al. Prostasin, serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst, 2001, 93 (19): 1458
  • 5Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins [J]. Cell, 1979,16(4) : 885-893.
  • 6Bao LH, Sakaguchi H, Fujimoto J, et al. Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers [J].J Biomed Sci, 2007,14(3):373-381.
  • 7Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer[J].Gynecol Oncol, 2005,99 (2) : 267-277.
  • 8Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer [J]. JAMA, 2002,287 (13) : 1671-1679.
  • 9Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies [J]. Clin Cancer Res, 2004, 10( 1 ) : 184-190.
  • 10Denhardt DT, Mistretta D, Chambers AF, et al. Transcriptional regulation of osteopontin and the metastatic phenotype:evidence for a ras-activated enhancer in the human open promoter [ J ]. Clin Exp Metastasis, 2003,20 ( 1 ) : 77-84.

共引文献97

同被引文献9

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部